Rapid Clinical Responses in a Phase 2 Trial of HLX79 (E-602), a First-in-Class Human Sialidase-Fc Fusion Protein, Plus HLX01 (Biosimilar Rituximab) in Membranous Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0840; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; P2 | "Fully unblinded data including biomarker analyses will be presented at the conference. Change from baseline in 24-hour urine protein and serum albumin at Week 12"
Clinical • P2 data • Fibrosis • Glomerulonephritis • Immunology • Nephrology • Renal Disease
|
|
Zhilian Li; Xueqing Yu; Qiuling Fan; Li Zuo; Deguang Wang; Rong Lv; Junxia Wang; Zhiming Ye; Hui Xu; Leping Shao Shao; Yan Yan; Huijuan Mao; Aimin Zhong; Cheng Chen; Wanhong Lu; Lizhi Cao; Louis Brenner; Li Peng; James W. Broderick; Yunna Zang; Yating Wang; Lin Han
|